Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 125 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter

  1. Radioactive iodine: What is the clinical and cost effectiveness of RAI after total or completion thyroidectomy for people with T2 disease and no adverse pathological features?

    the clinical and cost effectiveness of RAI after total or completion thyroidectomy for people with T2 disease and no adverse...

  2. External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer?

    effectiveness of external beam radiotherapy for people with residual or recurrent thyroid cancer? Any explanatory notes(if applicable)...

  3. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

  4. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

    Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

  5. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

  6. Thyroid disease

    Awaiting development [GID-QS10088] Expected publication date: TBC

  7. Percutaneous Laser Ablation (PLA) for benign thyroid nodules

    Register an interest in this interventional procedure   ...

  8. Teprotumumab for treating thyroid eye disease ID 6432

    Awaiting development [GID-TA11531] Expected publication date: TBC

  9. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 30 April 2025

  10. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the

  11. Cost saving guidance

    NICE guidance that could generate cost savings.

  12. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  13. Past appeals and decisions

    TA928 Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine 19...

  14. Managed access

    Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

  15. Lithium Support Service provided by community pharmacists

    patient is having their lithium levels monitored every three months and their thyroid function and renal function monitored every six...